DK2091949T3 - Indolderivater som S1P1-receptor agonister - Google Patents

Indolderivater som S1P1-receptor agonister

Info

Publication number
DK2091949T3
DK2091949T3 DK07857808.5T DK07857808T DK2091949T3 DK 2091949 T3 DK2091949 T3 DK 2091949T3 DK 07857808 T DK07857808 T DK 07857808T DK 2091949 T3 DK2091949 T3 DK 2091949T3
Authority
DK
Denmark
Prior art keywords
receptor agonists
indole derivatives
indole
derivatives
agonists
Prior art date
Application number
DK07857808.5T
Other languages
English (en)
Inventor
Mahmood Ahmed
James Myatt
David Norton
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2091949(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK2091949T3 publication Critical patent/DK2091949T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
DK07857808.5T 2006-12-21 2007-12-19 Indolderivater som S1P1-receptor agonister DK2091949T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds
PCT/EP2007/064185 WO2008074821A1 (en) 2006-12-21 2007-12-19 Indole derivatives as s1p1 receptor agonists

Publications (1)

Publication Number Publication Date
DK2091949T3 true DK2091949T3 (da) 2011-07-18

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07857808.5T DK2091949T3 (da) 2006-12-21 2007-12-19 Indolderivater som S1P1-receptor agonister
DK10158582.6T DK2206710T3 (da) 2006-12-21 2007-12-19 Indolderivater som s1p1-receptor agonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10158582.6T DK2206710T3 (da) 2006-12-21 2007-12-19 Indolderivater som s1p1-receptor agonister

Country Status (33)

Country Link
US (1) US8101775B2 (da)
EP (2) EP2206710B1 (da)
JP (1) JP5309034B2 (da)
KR (1) KR101495927B1 (da)
CN (1) CN103012390B (da)
AR (1) AR064452A1 (da)
AT (1) ATE509927T1 (da)
AU (1) AU2007336224B2 (da)
BR (1) BRPI0721127A2 (da)
CA (1) CA2673468C (da)
CL (1) CL2007003755A1 (da)
CR (2) CR10922A (da)
CY (2) CY1111702T1 (da)
DK (2) DK2091949T3 (da)
DO (1) DOP2009000133A (da)
EA (1) EA017406B1 (da)
ES (1) ES2389879T3 (da)
HK (2) HK1140761A1 (da)
HR (2) HRP20110456T1 (da)
IL (1) IL199187A (da)
JO (1) JO2701B1 (da)
MA (1) MA30999B1 (da)
MX (1) MX2009006882A (da)
MY (2) MY148470A (da)
NO (1) NO20092385L (da)
NZ (1) NZ577387A (da)
PE (2) PE20081398A1 (da)
PL (2) PL2206710T3 (da)
PT (2) PT2206710E (da)
SG (1) SG177914A1 (da)
SI (2) SI2091949T1 (da)
TW (1) TWI393564B (da)
WO (1) WO2008074821A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2453372T3 (es) 2006-04-03 2014-04-07 Astellas Pharma Inc. Derivados de oxadiazol como agonistas de S1P1
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
KR20090130062A (ko) * 2007-04-19 2009-12-17 글락소 그룹 리미티드 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
NZ589617A (en) 2008-05-14 2012-06-29 Scripps Research Inst 3-(Inden-4-yl)-5-(phenyl)-1,2,4-oxadiazole and 3-(tetralin-5-yl)-5-(phenyl)-1,2,4-oxadiazole derivatives
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
JP2011524880A (ja) * 2008-06-20 2011-09-08 グラクソ グループ リミテッド 化合物
HUE030424T2 (en) 2008-07-23 2017-05-29 Arena Pharm Inc Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
US9149459B2 (en) * 2008-07-23 2015-10-06 Novartis Ag Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
SI2342205T1 (sl) * 2008-08-27 2016-09-30 Arena Pharmaceuticals, Inc. Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
BRPI0923178A2 (pt) * 2008-12-18 2016-02-16 Merck Serono Sa derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EA024801B1 (ru) 2009-11-13 2016-10-31 Рецептос Ллк Селективные модуляторы рецептора сфингозин-1-фосфата
US20120283297A1 (en) * 2009-12-18 2012-11-08 Glaxo Wellcome House Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
ES2937386T3 (es) 2010-01-27 2023-03-28 Arena Pharm Inc Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo
WO2011109471A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
EP2560969B1 (en) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
ES2548258T3 (es) 2010-09-24 2015-10-15 Bristol-Myers Squibb Company Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
BR112013019683B1 (pt) 2011-02-07 2022-04-19 Biogen Inc Compostos que modulam s1p, composição farmacêutica, e uso dos mesmos
WO2012158550A2 (en) 2011-05-13 2012-11-22 Receptos, Inc. Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
WO2018014862A1 (zh) * 2016-07-22 2018-01-25 南京明德新药研发股份有限公司 S1p1激动剂及其应用
CA3038106A1 (en) 2016-09-29 2018-04-05 Celgene International Ii Sarl Compounds and methods for treating lupus
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN110545848A (zh) 2017-02-16 2019-12-06 艾尼纳制药公司 用于治疗具有肠外表现的炎症性肠病的化合物和方法
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
JP2023513575A (ja) * 2020-02-11 2023-03-31 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性な環状アミン化合物
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
US20060252741A1 (en) * 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
CN1859908A (zh) 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
EP1760071A4 (en) 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
MX2007010112A (es) 2005-02-25 2007-10-12 Ono Pharmaceutical Co Compuesto indol y uso del mismo.
RU2404178C2 (ru) 2005-03-23 2010-11-20 Актелион Фармасьютиклз Лтд Новые производные тиофена в качестве агонистов рецептора сфингозин-1-фосфата-1
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
AU2006256968A1 (en) 2005-06-08 2006-12-14 Novartis Ag Polycyclic oxadiazoles or I soxazoles and their use as SIP receptor ligands
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) * 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
ES2453372T3 (es) * 2006-04-03 2014-04-07 Astellas Pharma Inc. Derivados de oxadiazol como agonistas de S1P1
AU2007292993B2 (en) 2006-09-07 2013-01-24 Idorsia Pharmaceuticals Ltd Pyridin-4-yl derivatives as immunomodulating agents
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
KR20090130062A (ko) * 2007-04-19 2009-12-17 글락소 그룹 리미티드 스핑고신 １―포스페이트 (ｓ１ｐ) 효능제로서 사용하기 위한 옥사디아졸 치환된 인다졸 유도체

Also Published As

Publication number Publication date
CN103012390A (zh) 2013-04-03
MY156822A (en) 2016-03-31
BRPI0721127A2 (pt) 2014-03-11
CR10922A (es) 2009-08-12
PT2091949E (pt) 2011-07-13
EP2091949B1 (en) 2011-05-18
JO2701B1 (en) 2013-03-03
US20100113796A1 (en) 2010-05-06
PT2206710E (pt) 2012-09-10
KR20090092290A (ko) 2009-08-31
NZ577387A (en) 2012-01-12
TWI393564B (zh) 2013-04-21
SI2091949T1 (sl) 2011-08-31
CR20140316A (es) 2014-08-20
PE20081398A1 (es) 2008-11-19
KR101495927B1 (ko) 2015-02-25
ES2389879T3 (es) 2012-11-02
SI2206710T1 (sl) 2012-10-30
ATE509927T1 (de) 2011-06-15
DOP2009000133A (es) 2009-08-15
HRP20110456T1 (hr) 2011-07-31
PL2091949T3 (pl) 2011-10-31
CL2007003755A1 (es) 2008-08-22
EP2091949A1 (en) 2009-08-26
CY1111702T1 (el) 2015-10-07
CA2673468A1 (en) 2008-06-26
IL199187A (en) 2015-04-30
PL2206710T3 (pl) 2012-11-30
EP2206710B1 (en) 2012-07-04
JP5309034B2 (ja) 2013-10-09
MY148470A (en) 2013-04-30
EA200970612A1 (ru) 2009-10-30
WO2008074821A1 (en) 2008-06-26
MA30999B1 (fr) 2009-12-01
IL199187A0 (en) 2010-03-28
CN103012390B (zh) 2015-08-26
NO20092385L (no) 2009-08-24
CA2673468C (en) 2015-06-02
AR064452A1 (es) 2009-04-01
CY1113131T1 (el) 2016-04-13
AU2007336224A1 (en) 2008-06-26
EA017406B1 (ru) 2012-12-28
JP2010513397A (ja) 2010-04-30
AU2007336224B2 (en) 2013-01-10
HK1130255A1 (en) 2009-12-24
SG177914A1 (en) 2012-02-28
HRP20120685T1 (hr) 2012-09-30
TW200843736A (en) 2008-11-16
EP2206710A1 (en) 2010-07-14
MX2009006882A (es) 2009-07-03
HK1140761A1 (en) 2010-10-22
US8101775B2 (en) 2012-01-24
DK2206710T3 (da) 2012-08-27
PE20121076A1 (es) 2012-09-05

Similar Documents

Publication Publication Date Title
DK2091949T3 (da) Indolderivater som S1P1-receptor agonister
DK2069322T3 (da) THIOPHENDERIVATER SOM S1P1/EDG1-receptoragonister
DK1856110T3 (da) Oxyindol derivater som 5HT4-receptor agonister
DK2125797T3 (da) Aminopyridinderivater som s1p1/edg1-receptoragonister
DK1863474T3 (da) Hidtil ukendte thiophenderivater som sphingosin-1-phosphat-1-receptoragonister
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
IL192657A (en) Theophenic history as 1edg / 1p1s receptor agonists
BRPI0715324A2 (pt) Composto de indol
DK2195311T3 (da) Pyridinderivater som S1P1/EDG1-receptormodulatorer
DK2225231T3 (da) Aminotriazolderivater som alx-agonister
DK2066669T3 (da) Adenosinderivater som A2A-receptoragonister
DK2144897T3 (da) 8-Oxy-quinolinderivater som bradykinin B2-receptormodulatorer
DK2094658T3 (da) Tetrahydrocyclopenta[B]indolforbindelser som androgenreceptormodulatorer
ATE549350T1 (de) Neuropeptid-2-rezeptor-agonisten
DK1989196T3 (da) Piperidinoylpyrrolidiner som melanocortin-type 4-receptoragonister
IL198931A0 (en) Benzamide derivatives as ep4 receptor agonists
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
DK2049480T3 (da) 2-arylindolderivater som mPGES-1-hæmmere
DK1899324T3 (da) Benzimidazolcarboxamid-forbindelser som 5-HT4-receptoragonister
DK2148873T3 (da) 4-alkoxypyridazinderivater som hurtigt dissocierende dopamin 2- receptorantagonister
DK1749001T3 (da) 3-piperidinylisochroman-5-ol som dopaminagonister
DK1912976T3 (da) Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister
DK2132185T3 (da) Pyrimidinyl-piperaziner nyttige som dopamin-D3/D2-receptorligander
DK1896460T3 (da) Benzofuranylderivater som 5-HT6-receptorinhibitorer